Genome-wide screening reveals producer-cell modifications that improve virus-like particle production and delivery potency
Authors:
Open Access
- 24 April 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Engineered virus-like particles (eVLPs) are promising vehicles for transient delivery of gene editing agents. While extensive particle engineering has yielded efficient eVLPs, it remains underexplored whether engineering the cells used to produce eVLPs could further improve eVLP properties. We report an unbiased genome-wide screening approach to systematically investigate how genetic perturbations in producer cells influence eVLP production. This approach generates eVLPs loaded with guide RNAs that identify the genetic perturbation in the cell that produced a particular particle; the abundance of each guide RNA in eVLPs therefore reflects how the corresponding genetic perturbation influences eVLP production or cargo loading. We apply this approach to identify several genes that regulate eVLP cargo expression and loading into particles during the production process. Leveraging these insights, we engineer producer cells that support increased eVLP cargo packaging and a 2- to 9-fold increase in eVLP delivery potency across several cargo, particle, and target-cell types in cultured cells and in mice. Our findings suggest the potential of producer-cell engineering as a useful strategy for improving the utility of eVLPs and related delivery methods.Keywords
All Related Versions
This publication has 57 references indexed in Scilit:
- Engineered nucleocytosolic vehicles for loading of programmable editorsCell, 2025
- Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid processMolecular Therapy - Methods & Clinical Development, 2024
- Therapeutic in vivo delivery of gene editing agentsCell, 2022
- Engineered virus-like particles for efficient in vivo delivery of therapeutic proteinsCell, 2022
- Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineeringCell Reports, 2021
- Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA ConstructMolecular Therapy - Methods & Clinical Development, 2020
- Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free MediaMolecular Therapy - Methods & Clinical Development, 2020
- CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV VectorsCell, 2020
- Molecular Basis of RNA Polymerase III Transcription Repression by Maf1Cell, 2010
- Mammalian Maf1 Is a Negative Regulator of Transcription by All Three Nuclear RNA PolymerasesMolecular Cell, 2007